Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5539534 | 0.98 | HRH3 (0.49) | DRD4DRD2DRD3ALDH3A1KCNH2 | |
| SCHEMBL9697050 | 0.98 | HRH3 (0.49) | DRD4DRD2DRD3ALDH3A1KCNH2 | |
| SCHEMBL9697553 | 0.98 | HRH3 (0.49) | DRD4DRD2DRD3ALDH3A1KCNH2 | |
| SCHEMBL9695895 | 0.98 | HRH3 (0.49) | DRD4DRD2DRD3ALDH3A1KCNH2 | |
| SCHEMBL5540021 | 0.94 | DRD4 (0.51) | DRD4DRD2DRD3ALDH3A1KCNH2 | |
| SCHEMBL5536818 | 0.88 | DRD4 (0.49) | DRD4DRD2DRD3ALDH3A1KCNH2 | |
| SCHEMBL9770302 | 0.83 | ALDH3A1 (0.62) | DRD4DRD2DRD3ALDH3A1KCNH2 | |
| SCHEMBL30514014 | 0.81 | HRH3 (0.61) | DRD4DRD2DRD3ALDH3A1KCNH2 | |
| SCHEMBL11815991 | 0.81 | HRH3 (0.61) | DRD4DRD2DRD3ALDH3A1KCNH2 | |
| SCHEMBL11325793 | 0.81 | ALDH1A1 (0.53) | DRD4DRD2DRD3ALDH3A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-6121475-A | Preparation of optically active β-hydroxyester derivatives and platinum-containing catalyst | UBE INDUSTRIES, LTD. (JP) | 2000-09-19 | — | — | US | disclosed |
| EP-0973936-A1 | COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC AMINOTHIOETHER ACIDS | ELI LILLY AND COMPANY (US) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998046786-A1 | COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC AMINOTHIOETHER ACIDS | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1992001447-A1 | 2-CYCLOPROPYLACETIC ACID DERIVATIVES | SANDOZ LTD. (CH) | 1992-02-06 | — | — | WO | disclosed |
| US-4933365-A | ANTIFLAMMATORY AGENTS, ANTIALLERGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-06-12 | — | — | US | disclosed |
| WO-1989005142-A1 | PHOSPHOLIPASE A2 INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-06-15 | — | — | WO | disclosed |
| US-4788304-A | ANTIALLERGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-11-29 | — | — | US | disclosed |
| US-4788306-A | Fluorooxirane carboxylates as hypoglycemic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-11-29 | — | — | US | disclosed |
| EP-0283168-A2 | Fluorooxirane carboxylates | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | DRD4 368/4885DRD2 542/4885DRD3 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.